Chen Haiquan

A thoracic surgeon and pioneer in the international field of personalized surgical treatment for early-stage lung cancer. He identified a novel epidemiological characteristic—namely, the high incidence of early-stage lung cancer among young, female, non-smoking individuals in China, with GGO-associated lung cancer being predominant; he recognized that GGO-associated lung cancer represents a distinct clinical subtype and a unique phase in the natural course of lung cancer; he proposed the innovative concept of a "curative window period for early-stage lung cancer"; he introduced and established the new paradigm of personalized diagnosis and treatment as well as a novel clinical practice framework known as "Lung Cancer Minimally Invasive Surgery 3.0"; he pioneered the techniques of "frozen section pathology-guided sublobar resection" and "selective lymph node dissection in lung cancer surgery." The postoperative 5-and 10-year survival rates for patients with early-stage lung cancer under his care rank among the highest internationally. A series of his research studies have clarified the optimal surgical approach and the extent of lymph node dissection for mid-and lower-esophageal squamous cell carcinoma, making significant contributions to elevating the international standing and influence of China's thoracic surgery community.

Vice President of the Non-Small Cell Lung Cancer Committee, Chinese Anti-Cancer Association; Former Vice President of the Thoracic Surgeons Branch, Chinese Medical Doctor Association; Former International Council Member of the American Society of Thoracic Surgeons (STS); Former Council Member of the Asian Society for Cardiothoracic Surgery (ASCVTS); Chairperson of the Thoracic Surgery Branch, Shanghai Medical Association; Chairperson of the Lung Cancer Professional Committee, Shanghai Anti-Cancer Association; Founder of the Eastern Thoracic Oncology Collaborative Project (ECTOP); Member and Member Development Committee Member of the American Thoracic Society (AATS); Fellow of the Royal College of Surgeons of England (RCS); Member of the European Society of Thoracic Surgeons (ESTS); Editorial Board Member of J Thorac Cardiovasc Surg., Associate Editor of J Cancer Res Clin, Associate Editor of J Thorac Oncol, and Associate Editor for the ASO Specialty Section; Former Member of the Education Committee and the Clinical Practice Standards Committee of the American Thoracic Society (AATS).

As the corresponding author, he has published over 250 research papers in internationally renowned journals such as *Cancer Cell*, *Annals of Surgery*, *JCO*, *JTO*, *NC*, *CR*, *JTCVS*, and *Chest*; among these, 33 papers have been cited 41 times across 117 international guidelines for the diagnosis and treatment of lung cancer. He has led numerous research projects, including a Key Project funded by the National Natural Science Foundation of China. He was invited to chair the development of the 2023 American Thoracic Society (AATS) Expert Consensus on the Diagnosis and Management of Ground-Glass Nodules and was awarded the 2021 Schuster Distinguished Lectureship and the 2024 Sugarbaker Lectureship at Brigham and Women's Hospital, Harvard University. Since 2008, he has been frequently invited to deliver specialized lectures at several leading medical institutions, including the University of Pittsburgh Medical Center, Massachusetts General Hospital (Harvard University), Memorial Sloan Kettering Cancer Center (MSKCC), Vanderbilt University Medical Center, University of Zurich Medical Center (Switzerland), and KU Leuven Medical Center (Belgium).

Receives the Special Government Allowance from the State Council and has been honored as a "National Distinguished Physician" – awarded the titles of "Outstanding Achievement,"  "Shanghai Leading Talent," and "Shanghai Outstanding Academic Discipline Leader." Recipient of the First Prize for Shanghai Science and Technology Progress Award, the First Prize of the Chinese Medical Science and Technology Award, the First Prize of the China Anti-Cancer Association Science and Technology Award, and the First Prize of the Huaxia Medical Science and Technology Award.